Last reviewed · How we verify
X: Chidamide
At a glance
| Generic name | X: Chidamide |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy (PHASE2)
- Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia (PHASE2)
- CR-CHOP+X in Previously Untreated DEL (PHASE2)
- Dynamic CtDNA-guided Targeted Therapy in DLBCL (PHASE2)
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (PHASE2)
- Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma (PHASE2)
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL (PHASE2)
- Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- X: Chidamide CI brief — competitive landscape report
- X: Chidamide updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI